Amgen (NASDAQ:AMGN) recently shared new data on IMDELLTRA TM (tarlatamab-dlle), a novel delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE ® ) molecule at the 2024 World Conference on Lung Cancer (WCLC) in San Diego. IMDELLTRA was featured in two oral presentations during the “DLL3 Targeting BiTE Therapies in SCLC” session at 2:00 p.m. PDT.
The first presentation highlighted data from the global Phase 1b DeLLphi-303 study, showcasing the combination of IMDELLTRA with PD-L1 inhibitors in first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC). The second presentation focused on long-term results from the Phase 2 DeLLphi-301 study in previously treated ES-SCLC patients.
Dr. Jay Bradner, the Executive Vice President of Research and Development and Chief Scientific Officer at Amgen, expressed enthusiasm for the sustained benefits of IMDELLTRA in patients with extensive-stage small cell lung cancer. He emphasized the importance of delivering targeted immunotherapy to more individuals affected by this aggressive form of cancer.
The Phase 1b DeLLphi-303 study demonstrated a manageable safety profile and positive outcomes when IMDELLTRA was combined with PD-L1 inhibitors in first-line maintenance therapy for ES-SCLC. Key findings included a disease control rate of 62.5% and notable progression-free and overall survival rates. The study also highlighted the tolerability of IMDELLTRA in combination with different PD-L1 inhibitors.
Dr. Sally Lau, an Oncologist and Assistant Professor, shared her perspective on the potential of tarlatamab as a breakthrough for patients with ES-SCLC. The study data supported the ongoing evaluation of IMDELLTRA in the Phase 3 DeLLphi-305 trial.
In conclusion, the extended follow-up data from the Phase 2 DeLLphi-301 study demonstrated sustained anticancer activity and a favorable safety profile with IMDELLTRA in ES-SCLC patients previously treated with platinum-based chemotherapy.
Amgen’s commitment to advancing innovative treatments for cancer, including IMDELLTRA, underscores its position as a leader in biotechnology and healthcare. For more information on the study findings and IMDELLTRA, please visit the referenced sources.
